Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
55 studies found for:    Tuberous Sclerosis
Show Display Options
Rank Status Study
21 Recruiting The Cognitive Variability in NF1 and TSC Monozygotic Twins
Conditions: Neurofibromatosis Type I;   Tuberous Sclerosis Complex
Intervention:
22 Recruiting Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
Conditions: TSC;   Tuberous Sclerosis Complex;   Epilepsy
Intervention: Device: epilepsy early diagnosis protocol
23 Recruiting Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France
Condition: Tuberous Sclerosis Complex
Intervention:
24 Not yet recruiting Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Condition: Tuberous Sclerosis Complex
Interventions: Drug: Vigabatrin;   Drug: Placebo
25 Recruiting Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
Condition: Tuberous Sclerosis Complex
Intervention: Behavioral: JASPER
26 Active, not recruiting A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001;   Drug: Placebo
27 Completed RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: RAD001
28 Not yet recruiting Topical Everolimus in Patients With Tuberous Sclerosis Complex
Condition: Facial Angiofibromas
Interventions: Drug: Everolimus;   Drug: Placebo
29 Recruiting A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex.
Conditions: Tuberous Sclerosis Complex;   Seizures
Interventions: Drug: GWP42003-P;   Drug: Placebo
30 Enrolling by invitation An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex.
Conditions: Tuberous Sclerosis Complex;   Seizures
Intervention: Drug: GWP42003-P
31 Unknown  Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
Condition: Complex Partial Seizures
Intervention: Drug: vigabatrin
32 Completed Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Condition: Facial Angiofibroma
Intervention: Drug: Rapamune
33 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
34 Terminated Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Conditions: Autism;   Tuberous Sclerosis
Intervention:
35 Active, not recruiting Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Condition: Tuberous Sclerosis Complex
Intervention:
36 Completed Topical Rapamycin to Erase Angiofibromas in TSC
Conditions: Angiofibromas;   Tuberous Sclerosis
Interventions: Drug: Placebo;   Drug: Rapamycin
37 Completed Rapalogues for Autism Phenotype in TSC: A Feasibility Study
Conditions: Tuberous Sclerosis Complex;   Self-injury;   Autism
Interventions: Drug: Sirolimus;   Drug: Everolimus
38 Completed Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis
Condition: Angiomyolipoma
Intervention: Drug: Sirolimus
39 Recruiting A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Conditions: Epilepsy;   Tuberous Sclerosis Complex;   Focal Cortical Dysplasia
Intervention: Drug: Everolimus
40 Completed Doxycycline In Lymphangioleiomyomatosis (LAM)
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis
Interventions: Drug: Doxycycline;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-55) Show next page of results    Last Page
Indicates status has not been verified in more than two years